Research and Development

Showing 15 posts of 9573 posts found.

Netris Pharma doses first patient in pancreatic cancer study

March 29, 2023 Research and Development

Netris Pharma has announced that it has dosed its first patient in the Lap-NET1 study for the safety and efficacy …

AbbVie’s upadacitinib meets primary endpoint in trial for systemic lupus erythematosus

March 29, 2023 Research and Development

AbbVie has shared that upadacitinib (Rinvoq) has been shown to be effective in treating patients with moderately-to-severely-active systemic lupus erythematosus …

Novo Nordisk announces results from phase 3 PIONEER PLUS trial

March 28, 2023 Research and Development

Novo Nordisk has announced headline results from the phase 3b PIONEER PLUS trial for the safety and efficacy of once-daily …

GSK shares promising clinical trial results for endometrial cancer therapy

March 28, 2023 Research and Development

GSK has announced promising results from part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) alongside standard-of-care chemotherapy …

Novartis announces positive results from phase 3 trial of Kisqali for early breast cancer

March 27, 2023 Research and Development

Novartis has announced positive results from its phase 3 NATALEE trial assessing Kisqali (ribociclib) along with endocrine therapy (ET) in …

Biogen shares FDA decisions on ALS drug

March 23, 2023 Research and Development

US-based Biogen has announced two decisions the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee made surrounding its ALS …

Kite’s Yescarta CAR T-cell therapy shows statistically significant improvement in overall survival

March 22, 2023 Research and Development

Kite has announced the primary overall survival (OS) analysis results of a phase 3 study into Yescarta for the treatment …

Faron Pharmaceuticals announces positive FDA feedback for solid tumour therapy

March 22, 2023 Research and Development

Faron Pharmaceuticals, a clinical stage biopharmaceutical company, has revealed positive FDA feedback and recommendations for its monotherapy for solid tumour …

First candidate from Nurix-Gilead Sciences collaboration exclusively licensed

March 21, 2023 Research and Development

US-based Gilead Sciences and Nurix have announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein …

AbbVie shares results from study for new psoriasis therapy

March 20, 2023 Research and Development

AbbVie has announced new 52-week data from a study assessing the efficacy of new IL-23 inhibitor, Skyrizi (risankizumab). Patients with …

QurAlis Corporation announces programme which targets UNC13A mis-splicing in neurodegenerative diseases

March 20, 2023 Research and Development

US-based clinical-stage biotechnology QurAlis Corporation has announced the launch of its newest programme to treat neurodegenerative diseases like ALS and …

Seamless Therapeutics launches with $12.5m in financing

March 16, 2023 Research and Development

Seamless Therapeutics, a biotech focusing on the therapeutic potential of gene therapies, has announced it received $12.5m (€11.8m) in seed …

GSK shares positive results from meningococcal disease vaccine trial

March 14, 2023 Research and Development

GSK has announced positive results from its vaccine candidate trial for meningococcal, which is a significant cause of meningitis and …

Occlutech launches FROST-HF study of heart failure device

March 14, 2023 Research and Development

Occlutech has announced that it has recruited its first patient in the FROST-HF study, which aims to investigate the company’s …

Acadia Pharmaceuticals awaits FDA decision for first-of-its-kind Rett syndrome drug

March 10, 2023 Research and Development

Acadia Pharmaceuticals is aiming to follow in the footsteps of Reata Pharmaceuticals, who won approval for its novel drug to …
The Gateway to Local Adoption Series

Latest content